Skip to main content
OpenTrials
Completed

NCT Number: NCT04230226

Acute Study on Muscle Soreness, Damage, and Performance

The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Soreness, Muscle Damage Muscle Muscular Diseases Musculoskeletal Diseases Musculoskeletal Pain Myalgia Nervous System Diseases Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Performance Enhancing Product Use Signs and Symptoms

Age range

25 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is an adult between the ages of 25-50 years
  • Participant has a recorded BMI of 20-35 kg/m2
  • Participant exercises less than 3 hours per week for at least 8 weeks preceding the study
  • Participant has provided written and dated informed consent to participate in the study
  • Participant is willing to and able to comply with the protocol
  • Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire
  • Participant agrees to maintain current diet and exercise routine during the study
  • Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise (acute) or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage
  • Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg

Exclusion criteria

  • Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement
  • Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D
  • Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment
  • Participant has gained or lost ≥ 8 lbs in the previous month
  • Participant has a known allergy or sensitivity to the placebo or active ingredients
  • Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study
  • Participant is pregnant or planning to become pregnant
  • Participant has any musculoskeletal condition prohibiting them from participation

Treatment and study plan

Pre-workout plus and protein recovery plus

Dietary Supplement

Study products consumed prior and after exercise

Placebo

Other

Placebo product consumed prior and after exercise

Primary outcomes

  1. Performance

    Time frame: baseline, 24 hours, 48 hours

    Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer.

Secondary outcomes

  1. Muscle soreness

    Time frame: baseline, 24 hours, 48 hours

    Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.)

  2. Creatine Kinase

    Time frame: baseline, 24 hours, 48 hours

    Change from baseline on muscle damage by measuring creatine kinase

  3. Isoprostanes

    Time frame: baseline, 24 hours, 48 hours

    Change from baseline on muscle damage by measuring isoprostanes

Sponsors and collaborators

Lead sponsor

Pharmanex

Industry

Collaborators

  • University of North Carolina, Chapel Hill

Registry information

Official study title

A Randomized, Double-blind, Placebo Controlled, Single-center Study to Determine the Effects of Pre-workout and Recovery Formulations on Soreness, Performance, Tolerance and Safety Outcomes in Healthy Adults Undergoing Training Program

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 18, 2020
Registry last updated
Nov 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.